Purpose: Ribonucleotide reductase (RR) is a therapeutic target for DNA replication^dependent diseases such as cancer. Here, a potent small interfering RNA (siRNA) duplex against the M2 subunit of RR (RRM2) is developed and shown to reduce the growth potential of cancer cells both in vitro and in vivo. Experimental Design: Three anti-RRM2 siRNAs were identified via computational methods, and the potency of these and additional ''tiling'' duplexes was analyzed in cultured cells via cotransfections using a RRM2-luciferase fusion construct. Knockdown of RRM2 by the best duplex candidates was confirmed directly by Western blotting. The effect of potent duplexes on cell growth was investigated by a real-time cell electronic sensing assay. Finally, duplex performance was tested in vivo in luciferase-expressing cells via whole animal bioluminescence imaging. Results: Moderate anti-RRM2 effects are observed from the three duplexes identified by computational methods. However, the tiling experiments yielded an extremely potent duplex (siR2B+5). This duplex achieves significant knockdown of RRM2 protein in cultured cells and has pronounced antiproliferative activity. S.c. tumors of cells that had been transfected with siR2B+5 preinjection grew slower than those of control cells. Conclusions: An anti-RRM2 siRNA duplex is identified that exhibits significant antiproliferative activity in cancer cells of varying human type and species (mouse, rat, monkey); these findings suggest that this duplex is a promising candidate for therapeutic development.Ribonucleotide reductase (RR) catalyzes the conversion of ribonucleoside 5 ¶-diphosphates into their corresponding 2 ¶-deoxyribonucleotides and is a rate-limiting step in the pathway for the production of 2 ¶-deoxyribonucleoside 5 ¶-triphosphates that are necessary for DNA replication. Human RR consists of two subunits, RRM1 and RRM2, and the expression of both proteins is required for enzymatic activity. RRM1 and RRM2 are encoded by different genes on separate chromosomes, and their mRNAs are differentially expressed throughout the cell cycle. The cellular RRM1 protein level is kept relatively stable through the entire cell cycle, whereas RRM2 is only expressed during the late G 1 /early S phase when DNA replication occurs (1).RR has long been an important target for controlling pathologies that depend on DNA replication. Inhibition of RR activity has been tested as potential therapy in anticancer, antiviral, antibacterial, and other antiparasitic settings. A recent review on RR inhibitors as anticancer agents has appeared (2). Numerous small-molecule inhibitors, such as hydroxyurea (approved for human use) and triapine (3), interact with subunit RRM2. These small molecules are not completely specific to the RRM2 protein, however, and work continues on the design of more specific and effective inhibitors (4).A recent approach to RR down-regulation involves the use of nucleic acid -based, gene-specific inhibition. Yen et al. (5) and Lee et al. (6) have shown that antisense...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.